Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $1.81M fell 0.8% year over year, behind the +30.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +94.1% a year.

Context

  • Depreciation & amortization amounted to 14.1% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.8% toward the trailing-twelve-month pace of +30.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.81M+0.1% QoQ
Last fiscal yearDec 2025
$7.23M+80.0% YoY
LTMMar 2026
$7.22M+30.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.8%——
1 year+80.0%——
3-year CAGR+94.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
7.23M USD
Year-over-year change
+80.0%
4-year CAGR
+79.2%

Depreciation & Amortization vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +30.0% is the 2nd highest of 8, against a peer median of -1.0%.
  • Depreciation & amortization amounts to 14.2% of revenue for CPH.TO, versus a peer median of 7.2%.
CPH.TO Competitors
Depreciation & Amortization for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$61.18M CAD+17.4%-3.3%12.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$40.12M CAD-6.9%-23.0%12.9%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$19.76M CAD+37.8%—7.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$16.25M USD-28.6%-9.8%6.2%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$14.19M CAD-37.1%-31.2%4.5%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$7.22M USD+30.0%+94.1%14.2%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$253K CAD+1.6%-2.8%9.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$101.93K USD-1.0%—0.2%
Peer median (excluding CPH.TO) —-1.0%-9.8%7.2%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.76M26.64M20.38M11.55M27.33M
Depreciation & Amortization701K989K1.23M4.02M7.23M
Deferred Income Tax(114K)(14.31M)(2.74M)(8.64M)(10.36M)
Stock-Based Compensation139K403K1.19M1.07M1.74M
Change in Working Capital4.68M(3.03M)(3.28M)8.95M5.32M
Accounts Receivables2.56M(144K)1.71M(8.77M)2.7M
Inventory(758K)(502K)(830K)3.6M(2.44M)
Accounts Payables(1.23M)(1.45M)532K1.28M527.07K
Other Working Capital4.11M(940K)(4.69M)12.85M4.53M
Other Non-Cash Items652K(109K)(788K)2.6M(1.01M)
Operating Cash Flow13.81M10.58M16M19.55M30.25M
Capital Expenditures0(81K)(144K)(44K)(28.49K)
Acquisitions (Net)0000132.28K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(123K)(80M)0
Investing Cash Flow0(81K)(144K)(80.04M)(72.24K)
Debt Repayment(828K)(56K)(111K)39.79M(35.61M)
Common Stock Issued0000218.76K
Common Stock Repurchased(1.72M)(1.99M)(5.56M)(176K)(5.48M)
Dividends Paid00000
Other Financing Activities75K132K426K(317K)(311.36K)
Financing Cash Flow(2.47M)(1.91M)(5.24M)39.3M(41.18M)
Effect of Forex Changes62K(292K)378K(786K)(194.92K)
Net Change in Cash11.41M8.29M10.99M(21.99M)(11.2M)
Free Cash Flow13.81M10.49M15.98M19.5M30.22M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.